Kindred At Home | |
625 Kenmoor Se Ave, Ste 306, Grand Rapids, Michigan 49546 | |
(616) 942-5744 | |
Name | Kindred At Home |
---|---|
Location | 625 Kenmoor Se Ave, Ste 306, Grand Rapids, Michigan |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 237222 |
Ownership Type | Proprietary |
Service Area Zip Codes | 45944, 48315, 48809, 48811, 48818, 48829, 48834, 48838, 48846, 48849, 48850, 48865, 48875, 48881, 48884, 48888, 48897, 49046, 49058, 49073, 49301, 49302, 49306, 49311, 49315, 49316, 49317, 49319, 49321, 49322, 49323, 49325, 49326, 49328, 49329, 49330, 49331, 49332, 49333, 49335, 49336, 49339, 49341, 49343, 49344, 49345, 49347, 49348, 49401, 49404, 49408, 49415, 49417, 49418, 49423, 49424, 49426, 49428, 49437, 49440, 49441, 49442, 49444, 49445, 49448, 49456, 49457, 49460, 49461, 49464, 49503, 49504, 49505, 49506, 49507, 49508, 49509, 49512, 49519, 49525, 49534, 49544, 49546, 49548 |
NPI Number | 1306876438 |
Organization Name | CENTERWELL CERTIFIED HEALTHCARE CORP. |
Doing Business As | CENTERWELL HOME HEALTH |
Address | 625 Kenmoor Ave Se, Suite 306, Grand Rapids, MI 49546 |
Phone Number | 616-942-5744 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
Quality Rating: |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 99.4 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 99.2 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 98.9 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 91.8 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 94.1 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.1 | 96.4 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 83.7 | 79.6 |
How often patients got better at getting in and out of bed | 83.9 | 81.1 |
How often patients got better at bathing | 87.2 | 82.3 |
How often patients’ breathing improved | 84 | 82.8 |
How often patients’ wounds improved or healed after an operation | 98.6 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 86.1 | 75 |
How often home health patients had to be admitted to the hospital | 15.4 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 19.2 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 73.8 | 94 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
The patient survey data of Kindred At Home is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 89 | 88 |
Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 81 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 81 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 72 | 78 |
News Archive
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
The Cancer Institute of New Jersey (CINJ) has been awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute.
Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in cancer cells regulate the altered metabolic state.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the first quarter ended March 31, 2010.
› Verified 8 days ago
Visiting Nurse Services Of Western Michigan Location: 1401 Cedar Ne, Grand Rapids, Michigan 49503 Ratings: Phone: (616) 486-3900 | |
Mary Free Bed At Home Location: 4280 Cascade Rd, Grand Rapids, Michigan 49546 Ratings: Phone: (616) 942-5570 | |
Atrio Home Health Location: 2100 Raybrook Se, Grand Rapids, Michigan 49546 Ratings: Phone: (616) 235-4663 | |
Mercy Health Home Care, Grand Rapids Location: 1430 Monroe Nw, Suite 120, Grand Rapids, Michigan 49505 Ratings: Phone: (616) 685-8800 | |
Kindred At Home Location: 625 Kenmoor Se Ave, Ste 306, Grand Rapids, Michigan 49546 Ratings: Phone: (616) 942-5744 | |
Porter Hills Home Health Care Location: 4450 Cascade Rd Se, Grand Rapids, Michigan 49546 Ratings: Phone: (616) 949-5140 |